Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 379

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 379
---
415278,612 1,132,376 1,902,367 2,159,946 Other programs1,172,927 1,483,901 2,415,035 3,534,513 Non-program expenses(2)1,583,015 1,535,804 2,787,399 2,843,168 Employee-related costs4,944,540 5,201,914 10,323,479 10,930,991 Stock-based compensation expense1,524,943 1,661,749 3,217,210 3,136,507 Depreciation and amortization84,527 90,533 169,788 180,742 Other segment items(3)(324,013)(833,820)(762,532)(1,851,741)Net loss$14,433,881 $14,079,927 $29,480,012 $28,387,756 (1) Includes direct research and development expenses.(2) Includes general and administrative expenses, in addition to facilities and other research and development expenses.(3) Includes interest income and other (income) expense.

22

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our interim condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and with our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including the audited consolidated financial statements and notes thereto. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical-stage oncology company outpacing cancer to help patients outlive their disease. We aim to achieve this goal through Deep Cyclic Inhibition® ("DCI") of clinically-validated core signaling pathways such as the mitogen-activated protein kinase ("MAPK") pathway, impacting cancer cells